SCHEMBL5041519

SCHEMBL5041519

FC(F)(F)c1ccccn1.FC(F)(F)c1ccccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
AHR P35869 1/20 0.47
TRPV4 Q9HBA0 1/20 0.44
KDM4E B2RXH2 2/20 0.43
CYP1A2 P05177 2/20 0.43
BLM P54132 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
METAP1 P53582 1/20 0.43
HIF1A Q16665 1/20 0.43
DOHH Q9BU89 1/20 0.43
P4HTM Q9NXG6 1/20 0.43
GAA P10253 1/20 0.42
MDM2 Q00987 1/20 0.42
LOXL2 Q9Y4K0 2/20 0.42
GABRA1 P14867 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL84051 1.00 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
SCHEMBL29401687 1.00 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
SCHEMBL29424134 1.00 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
Methane SCHEMBL8775730 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
Bromide SCHEMBL22440321 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
SCHEMBL28480196 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
Hydrochloric Acid SCHEMBL18039122 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
Hydrochloric Acid SCHEMBL30785438 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
SCHEMBL28002956 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E
SCHEMBL27951465 0.97 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRTRPV4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319099-B2 Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-20050209241-A1 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209241-A1 Benzoyl-piperazine derivatives SLC1A2, SLC18A2, SLC6A7 SMN1; SMN2 1268/4885L3MBTL1 2359/4885AHR 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.